Key result
Empagliflozin preserves eGFR and reduces heart failure or death vs. placebo after acute MI.
Why the study?
Does empagliflozin preserve kidney function and reduce heart failure or all-cause mortality in patients with acute myocardial infarction and risk for heart failure?
RCT (n=6,522)
Double-blind
randomized
Yes
Does empagliflozin preserve kidney function and reduce heart failure or all-cause mortality in patients with acute myocardial infarction and risk for heart failure?
Answers are grounded in this paper and cite their sources.
Empagliflozin preserves kidney function and safely reduces heart failure or mortality outcomes when initiated soon after acute myocardial infarction, regardless of baseline kidney function.
Data on the cardiovascular–kidney effects and safety of empagliflozin among patients with acute myocardial infarction are limited. EMPACT-MI (Study to Evaluate the Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients with Acute Myocardial Infarction) was a double-blind, multicenter clinical trial that randomized 6,522 patients with acute myocardial infarction and risk for heart failure to empagliflozin or placebo. Here we show in this secondary analysis that the mean estimated glomerular filtration rate at baseline was 76.1 ml min −1 1.73 m − 2 (s.d. = 19.9 ml min −1 1.73 m − 2 ), with longitudinal kidney function data available for 1,152 (17.7%) treated patients from select countries. By 24 months, compared with baseline, the estimated glomerular filtration rate was similar in the empagliflozin group but declined in the placebo group ( P = 0.01). Empagliflozin reduced the total adverse events of heart failure or all-cause mortality irrespective of kidney function ( P interaction = 0.30). Thirty-day adverse event rates were similar by treatment group and consistent across baseline kidney function. Empagliflozin had kidney-protective effects, reduced heart failure outcomes and was safe to initiate soon after acute myocardial infarction across baseline kidney function.
No takes yet. Share an insight, caveat, or question.
Aggarwal et al. (2025) conducted an RCT in Acute myocardial infarction and risk for heart failure (n=6,522). Empagliflozin vs. Placebo was evaluated on Estimated glomerular filtration rate by 24 months (p=0.01). Empagliflozin preserved estimated glomerular filtration rate by 24 months compared to placebo and reduced heart failure or all-cause mortality after acute myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: